Serotonin, or 5-hydroxytryptamine (5-HT), is an important neurotransmitter1,2 that activates the largest subtype family of G-protein-coupled receptors3. Drugs that target 5-HT1A, 5-HT1D, 5-HT1E and other 5-HT receptors are used to treat numerous disorders4. 5-HT receptors have high levels of basal activity and are subject to regulation by lipids, but the structural basis for the lipid regulation and basal activation of these receptors and the pan-agonism of 5-HT remains unclear. Here we report five structures of 5-HT receptor–G-protein complexes: 5-HT1A in the apo state, bound to 5-HT or bound to the antipsychotic drug aripiprazole; 5-HT1D bound to 5-HT; and 5-HT1E in complex with a 5-HT1E- and 5-HT1F-selective agonist, BRL-54443. Notably, the phospholipid phosphatidylinositol 4-phosphate is present at the G-protein–5-HT1A interface, and is able to increase 5-HT1A-mediated G-protein activity. The receptor transmembrane domain is surrounded by cholesterol molecules—particularly in the case of 5-HT1A, in which cholesterol molecules are directly involved in shaping the ligand-binding pocket that determines the specificity for aripiprazol. Within the ligand-binding pocket of apo-5-HT1A are structured water molecules that mimic 5-HT to activate the receptor. Together, our results address a long-standing question of how lipids and water molecules regulate G-protein-coupled receptors, reveal how 5-HT acts as a pan-agonist, and identify the determinants of drug recognition in 5-HT receptors.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Density maps and structure coordinates have been deposited in the Electron Microscopy Data Bank (EMDB) and the PDB with accession codes EMD-30971 and 7E2X for the apo–5-HT1A–Gi complex; EMD-30972 and 7E2Y for the 5-HT–5-HT1A–Gi complex; EMD-30973 and 7E2Z for the aripiprazole–5-HT1A–Gi complex; EMD-30974 and 7E32 for the 5-HT–5-HT1D–Gi complex; and EMD-30975 and 7E33 for the 5-HT–5-HT1E–Gi complex.
Berger, M., Gray, J. A. & Roth, B. L. The expanded biology of serotonin. Annu. Rev. Med. 60, 355–366 (2009).
Mohammad-Zadeh, L. F., Moses, L. & Gwaltney-Brant, S. M. Serotonin: a review. J. Vet. Pharmacol. Ther. 31, 187–199 (2008).
Hannon, J. & Hoyer, D. Molecular biology of 5-HT receptors. Behav. Brain Res. 195, 198–213 (2008).
Barnes, N. M. et al. International Union of Basic and Clinical Pharmacology. CX. Classification of receptors for 5-hydroxytryptamine; pharmacology and function. Pharmacol. Rev. 73, 310–520 (2021).
Dawaliby, R. et al. Allosteric regulation of G protein-coupled receptor activity by phospholipids. Nat. Chem. Biol. 12, 35–39 (2016).
Duncan, A. L., Song, W. & Sansom, M. S. P. Lipid-dependent regulation of ion channels and G protein-coupled receptors: insights from structures and simulations. Annu. Rev. Pharmacol. Toxicol. 60, 31–50 (2020).
van Meer, G., Voelker, D. R. & Feigenson, G. W. Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol. 9, 112–124 (2008).
Di Paolo, G. & De Camilli, P. Phosphoinositides in cell regulation and membrane dynamics. Nature 443, 651–657 (2006).
de Rubio, R. G. et al. Phosphatidylinositol 4-phosphate is a major source of GPCR-stimulated phosphoinositide production. Sci. Signal. 11, eaan1210 (2018).
Yen, H. Y. et al. PtdIns(4,5)P-2 stabilizes active states of GPCRs and enhances selectivity of G-protein coupling. Nature 559, 423–427 (2018).
Falkenburger, B. H., Jensen, J. B., Dickson, E. J., Suh, B. C. & Hille, B. Phosphoinositides: lipid regulators of membrane proteins. J. Physiol. 588, 3179–3185 (2010).
Seifert, R. & Wenzel-Seifert, K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch. Pharmacol. 366, 381–416 (2002).
Teitler, M., Herrick-Davis, K. & Purohit, A. Constitutive activity of G-protein coupled receptors: emphasis on serotonin receptors. Curr. Top. Med. Chem. 2, 529–538 (2002).
De Deurwaerdère, P., Bharatiya, R., Chagraoui, A. & Di Giovanni, G. Constitutive activity of 5-HT receptors: factual analysis. Neuropharmacology 168, 107967 (2020).
Berg, K. A., Harvey, J. A., Spampinato, U. & Clarke, W. P. Physiological and therapeutic relevance of constitutive activity of 5-HT2A and 5-HT2C receptors for the treatment of depression. Prog. Brain Res. 172, 287–305 (2008).
Gutierrez, M. G., Mansfield, K. S. & Malmstadt, N. The functional activity of the human serotonin 5-HT1A receptor is controlled by lipid bilayer composition. Biophys. J. 110, 2486–2495 (2016).
Winner, P. Triptans for migraine management in adolescents. Headache 42, 675–679 (2002).
Shimron-Abarbanell, D., Nöthen, M. M., Erdmann, J. & Propping, P. Lack of genetically determined structural variants of the human serotonin-1E (5-HT1E) receptor protein points to its evolutionary conservation. Brain Res. Mol. Brain Res. 29, 387–390 (1995).
Liang, Y. L. et al. Dominant negative G proteins enhance formation and purification of agonist-GPCR-G protein complexes for structure determination. ACS Pharmacol Transl Sci 1, 12–20 (2018).
Yin, W. et al. Crystal structure of the human 5-HT1B serotonin receptor bound to an inverse agonist. Cell Discov. 4, 12 (2018).
García-Nafría, J., Nehmé, R., Edwards, P. C. & Tate, C. G. Cryo-EM structure of the serotonin 5-HT1B receptor coupled to heterotrimeric Go. Nature 558, 620–623 (2018).
Carlson, M. L. et al. The peptidisc, a simple method for stabilizing membrane proteins in detergent-free solution. eLife 7, e34085 (2018).
Evans, K. L. J., Cropper, J. D., Berg, K. A. & Clarke, W. P. Mechanisms of regulation of agonist efficacy at the 5-HT1A receptor by phospholipid-derived signaling components. J. Pharmacol. Exp. Ther. 297, 1025–1035 (2001).
Pucadyil, T. J. & Chattopadhyay, A. Cholesterol modulates the antagonist-binding function of hippocampal serotonin1A receptors. Biochim. Biophys. Acta Biomembr. 1714, 35–42 (2005).
Kim, K. et al. Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor. Cell 182, 1574–1588 (2020).
Forster, E. A. et al. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur. J. Pharmacol. 281, 81–88 (1995).
Zhou, Q. T. et al. Common activation mechanism of class A GPCRs. eLife 8, e50279 (2019).
Kooistra, A.J. et al. GPCRdb in 2021: integrating GPCR sequence, structure and function. Nucleic Acids Res. 49, D335–D343 (2021).
Klein, M. T., Dukat, M., Glennon, R. A. & Teitler, M. Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: a comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationships. J. Pharmacol. Exp. Ther. 337, 860–867 (2011).
Xu, P. et al. Structures of the human dopamine D3 receptor-Gi complexes. Mol. Cell https://doi.org/10.1016/j.molcel.2021.01.003 (2021).
Davies, M. A., Sheffler, D. J. & Roth, B. L. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 10, 317–336 (2004).
Sjögren, B., Csöregh, L. & Svenningsson, P. Cholesterol reduction attenuates 5-HT1A receptor-mediated signaling in human primary neuronal cultures. Naunyn Schmiedebergs Arch. Pharmacol. 378, 441–446 (2008).
Chun, E. et al. Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure 20, 967–976 (2012).
Wang, C. et al. Structural basis for molecular recognition at serotonin receptors. Science 340, 610–614 (2013).
Roth, C. B., Hanson, M. A. & Stevens, R. C. Stabilization of the human β2-adrenergic receptor TM4–TM3–TM5 helix interface by mutagenesis of Glu1223.41, a critical residue in GPCR structure. J. Mol. Biol. 376, 1305–1319 (2008).
Maeda, S. et al. Development of an antibody fragment that stabilizes GPCR/G-protein complexes. Nat. Commun. 9, 3712 (2018).
Angiulli, G. et al. New approach for membrane protein reconstitution into peptidiscs and basis for their adaptability to different proteins. eLife 9, e53530 (2020).
Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
Zhang, K. Gctf: real-time CTF determination and correction. J. Struct. Biol. 193, 1–12 (2016).
Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519–530 (2012).
Kato, H. E. et al. Conformational transitions of a neurotensin receptor 1-Gi1 complex. Nature 572, 80–85 (2019).
Heymann, J. B. Guidelines for using Bsoft for high resolution reconstruction and validation of biomolecular structures from electron micrographs. Protein Sci. 27, 159–171 (2018).
Kang, Y. Y. et al. Cryo-EM structure of human rhodopsin bound to an inhibitory G protein. Nature 558, 553–558 (2018).
Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126–2132 (2004).
Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D 74, 519–530 (2018).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213–221 (2010).
Williams, C. J. et al. MolProbity: more and better reference data for improved all-atom structure validation. Protein Sci. 27, 293–315 (2018).
Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70–82 (2021).
Halgren, T. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47, 1750–1759 (2004).
Isberg, V. et al. Genetic GPCR residue numbers – aligning topology maps while minding the caps. Trends Pharmacol. Sci. 36, 22–31 (2015).
Šali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779–815 (1993).
Wu, E. L. et al. CHARMM-GUI Membrane Builder toward realistic biological membrane simulations. J. Comput. Chem. 35, 1997–2004 (2014).
Guvench, O. et al. CHARMM additive all-atom force field for carbohydrate derivatives and its utility in polysaccharide and carbohydrate-protein modeling. J. Chem. Theory Comput. 7, 3162–3180 (2011).
MacKerell, A. D. et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 102, 3586–3616 (1998).
Van Der Spoel, D. et al. GROMACS: fast, flexible, and free. J. Comput. Chem. 26, 1701–1718 (2005).
Hess, B., Kutzner, C., van der Spoel, D. & Lindahl, E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 4, 435–447 (2008).
Bussi, G., Donadio, D. & Parrinello, M. Canonical sampling through velocity rescaling. J. Chem. Phys. 126, 014101 (2007).
Aoki, K. M. & Yonezawa, F. Constant-pressure molecular-dynamics simulations of the crystal-smectic transition in systems of soft parallel spherocylinders. Phys. Rev. A 46, 6541–6549 (1992).
Hess, B. P-LINCS: a parallel linear constraint solver for molecular simulation. J. Chem. Theory Comput. 4, 116–122 (2008).
The cryo-EM data were collected at the Center of Cryo-Electron Microscopy, Zhejiang University, and at the Center of Cryo-Electron Microscopy, Shanghai Institute of Materia Medica. This work was partially supported by the National Key R&D Programs of China (2018YFA0507002); the Shanghai Municipal Science and Technology Major Project (2019SHZDZX02); the CAS Strategic Priority Research Program (XDB37030103) to H.E.X.; the National Key Basic Research Program of China (2019YFA0508800); the National Natural Science Foundation of China (81922071); the Zhejiang Province Natural Science Fund for Excellent Young Scholars (LR19H310001); Fundamental Research Funds for the Central Universities (2019XZZX001-01-06) to Y.Z.; the National Natural Science Foundation (31770796) and National Science and Technology Major Project (2018ZX09711002-002-002) to Y.J.; the Fund of Youth Innovation Promotion Association (2018319 Y8G7011009) to X.C.; the Science and Technology Commission of Shanghai Municipal (20431900100) and Jack Ma Foundation (2020-CMKYGG-05) to H.J.; the EU Horizon 2020, Innovative Training Network SAFER (765657) to I.A.S.; the Lundbeck Foundation (R163-2013-16327) and Novo Nordisk Foundation (NNF18OC0031226) to D.E.G. and K.H.; and a Wellcome Trust Investigator Award (104633/Z/14/Z) to C.V.R. and H.-Y.Y.
The authors declare no competing interests.
Peer review information Nature thanks Daniel Wacker and Daniel Rosenbaum for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
a, Analytical size-exclusion chromatography of the purified complex. b, SDS–PAGE and Coomassie blue stain of the purified complex. Experiments were repeated three times with similar results. c, Representative cryo-EM image (scale bar, 30 nm) from 4,179 movies and 2D averages (scale bar, 5 nm) of the 5-HT–5-HT1A–Gi complex. Experiments were repeated three times with similar results. d–f, Flow chart of cryo-EM data analysis and local resolution for the densities of the apo- (d), 5-HT-bound (e) and aripiprazole-bound (f) 5-HT1A–Gi complexes. g, ‘Gold-standard’ FSC curves. h, Local resolution for the density of water molecules (W1–W4) in the ligand-binding pocket of the apo-5-HT1A–Gi structure.
Extended Data Fig. 2 Sample preparation and cryo-EM of the 5-HT1D–Gi–scFv16 and 5-HT1E–Gi–scFv16 complexes.
a, b, Analytical size-exclusion chromatography and SDS–PAGE and Coomassie blue stain of the purified 5-HT1D–Gi–scFv16 complex (a) and the 5-HT1E–Gi–scFv16 complex (b). Experiments were repeated three times with similar results. c, Representative cryo-EM image (scale bar, 30 nm) from 4,375 movies and 2D averages (scale bar, 5 nm) of the 5-HT1D–Gi–scFv16 complex. d, Representative cryo-EM image (scale bar, 30 nm) from 5,249 movies and 2D averages (scale bar, 5 nm) of the 5-HT1E–Gi–scFv16 complex. e, f, Flow chart of cryo-EM data analysis, local resolution for the density and the ‘gold-standard’ FSC curves of the 5-HT1D–Gi–scFv16 complex (e) and the 5-HT1E–Gi–scFv16 complex (f).
a–c, The cryo-EM map of the apo–5-HT1A–Gi complex and the surrounding lipids are shown with different thresholds of 0.025 (a), 0.03 (b) and 0.04 (c). d, Interactions of PtdIns4P (here labelled as PI4P) at the 5-HT1A–Gi interface. e, Interaction of the PtdIns4P head group with the TM6, TM and Gαi pocket. Hydrogen bonds are shown with dashed lines. f, Comparison of the density fitting for PtdIns4P, phosphatidylinositol and PtdIns(4,5)P2 (here labelled as PIP2). The area of density that is not well fit is circled by a dashed line. g, 5-HT1A-mediated Gi activity is regulated by phosphatidylinositol, PtdIns4P and PtdIns(4,5)P2, with the greatest degree of regulation by PtdIns4P. GTPase-Glo assay was performed in LNMG buffer. Lower levels of residual GTP indicate higher levels of G-protein activity upon receptor-mediated GDP exchange for GTP and GTP hydrolysis. Data are mean ± s.d. of three independent experiments performed in technical triplicate. **P < 0.01, ***P < 0.001, ****P < 0.0001 (two-tailed paired t-test).
a, The model of the 5-HT1A–Gi complex shows multiple cholesterol molecules bound to the surface of 5-HT1A. The 5-HT1A–Gi complex is shown as surface and lipids are shown as sticks. b, Interactions of cholesterol molecule 1 (#1) with TM1 and TM7 of 5-HT1A. c, Interactions of cholesterol molecules 2 and 3 with 5-HT1A. d, The effect of cholesterol on the 5-HT potency to activate 5-HT1A. The effects of mutations at the binding residues of cholesterol molecule 1 on 5-HT-mediated activation of 5-HT1A (pEC50; the negative logarithm of EC50) were detected by NanoBiT recruitment assays. Data are mean ± s.d. from at least three independent experiments performed in technical triplicate. *P < 0.05, **P < 0.01 (two-tailed paired t-test).
a, Detection of the ligand-reduced activity and constitutive activity of human 5-HT1A by NanoBiT G-protein-recruitment assay. Three ligands—the full agonist 5-HT, the neutral antagonist WAY-100635 and the inverse agonist methiothepin—were used. Data are mean ± s.e.m. of three independent experiments performed in technical triplicate. b, Water molecules are coordinated in the ligand-binding pocket of the apo-5-HT1A structure. The density is shown at a cut-off of 3σ. c–f, Activation of 5-HT1A by 5-HT and binding to apo-5-HT1A by water molecules. Toggle switch in the 5-HT-bound 5-HT1A structure (c) and the apo-5-HT1A structure (e). PIF motif in the 5-HT-bound 5-HT1A structure (d) and the apo-5-HT1A structure (f). The 5-HT-bound 5-HT1A structure is coloured in turquoise; the apo-5-HT1A is coloured in green; 5-HT is coloured in orange. Aligned structures of the inactive-state 5-HT1B (bound to the inverse agonist methiothepin) and the intermediate-state 5-HT1B (bound to the agonist ERG) are coloured in grey and light grey. Conformational changes of the toggle-switch residue Trp3586 48 and the residue Phe3546.44, which is part of a conserved PIF motif, are illustrated by arrows. g–i, The hydrogen-bonding network of the ligand-binding pocket observed in the molecular dynamics simulations. Side view (g) and top view (h) of a hydrogen-bonding network linking the key residues of the active apo-5-HT1A receptor. i, Top view of water molecules accommodated in the inactive apo-5-HT1A receptor. The structure of the apo-5-HT1A is coloured in light blue. A representative conformation from the active apo-5-HT1A simulations is coloured in light green. A representative conformation from the inactive apo-5-HT1A simulations is coloured in grey. The structured water molecules W1 and W2 of the apo-5-HT1A–Gi complex structure are shown as spheres. Putative hydrogen bonds are shown with dashed lines.
a, d, g, j, Conformation of the ligand-binding pockets in 5-HT-bound 5-HT1A (a), 5-HT-bound 5-HT1D (d), BRL-54443-bound 5-HT1E (g) and aripiprazole-bound 5-HT1A (j). b, e, h, k, Diagram of ligand recognition for 5-HT in 5-HT1A (b), 5-HT in 5-HT1D (e), BRL-54443 in 5-HT1E (h), and aripiprazole in 5-HT1A (k). c, f, i, l, Ligand-binding pockets shown as surfaces. The orthosteric binding pocket is highlighted in orange.
Extended Data Fig. 7 Ligand-binding pocket mutagenesis data by NanoBiT Gi-protein-recruitment assay.
Data are mean ± s.e.m. from at least three independent experiments performed in technical triplicate. The EC50 ratio, EC50(mutant)/EC50(WT), represents the shift between the wild-type and mutant curves, and characterizes the effect of the mutations on receptor activation.
a, Dendrogram and sequence alignment on the basis of residues that line the 5-HT-binding pocket (cut-off of 5 Å). Identical residues are marked in white, whereas non-conserved residues are coloured by their physicochemical properties. b, Binding affinities (pKi values) for selected ligands of the 5-HT receptors (https://pdsp.unc.edu/pdspweb/).
a, Fitted regression model versus experimental binding affinities of 5-HT, 5-MeOT, 5-CT and donitriptan for the 5-HT GPCRs. b–d, 5-HT- (b), 5-CT- (c) and donitriptan-(d) induced Gi activation assay using NanoBiT for wild-type 5-HT1A, 5-HT1D and 5-HT1E receptors. Data are mean ± s.e.m. from at least three independent experiments performed in technical triplicate. e, 5-CT-induced Gi activation assay using NanoBiT for 5-HT1E, and concentration–response curves for G-protein-recruitment signals. Data are mean ± s.e.m. from at least three independent experiments performed in technical triplicate. f, g, The different side chains at the transmembrane domain (f) and at ECL2 (g) that determine the recognition for donitriptan among 5-HT1A, 5-HT1B, 5-HT1D and 5-HT1E. h, Docked pose of donitriptan in donitriptan-bound 5-HT1A (right), 5-HT1D (middle) and 5-HT1E (left).
About this article
Cite this article
Xu, P., Huang, S., Zhang, H. et al. Structural insights into the lipid and ligand regulation of serotonin receptors. Nature 592, 469–473 (2021). https://doi.org/10.1038/s41586-021-03376-8